B-cell targeted therapy of pemphigus

Area of Science:

• Immunodermatology
• Autoimmune Blistering Diseases
• Pharmacotherapy

Background:

• Pemphigus is an autoimmune disorder affecting skin and mucous membranes due to autoantibodies against desmoglein.
• Corticosteroids are first-line treatment but carry significant risks and burdens.
• Minimizing treatment risks while maximizing efficacy is a key challenge in pemphigus management.

Purpose of the Study:

• To review the current status and future directions of pemphigus treatment.
• To highlight the evolving role of B-cell targeted therapies.
• To discuss the potential of rituximab and Bruton's tyrosine kinase inhibitors.

Main Methods:

• Review of current literature on pemphigus treatment strategies.
• Focus on B-cell targeting agents, including rituximab.
• Discussion of emerging therapies like Bruton's tyrosine kinase inhibitors.

Main Results:

• B-cell targeting therapies, such as rituximab, represent a new era in pemphigus treatment.
• Rituximab is now approved for refractory pemphigus in major regions.
• Bruton's tyrosine kinase inhibitors show promise for future pemphigus management.

Conclusions:

• B-cell targeted therapies are crucial for optimizing pemphigus treatment efficacy and safety.
• Rituximab has established itself as a key therapeutic option.
• Bruton's tyrosine kinase inhibitors are anticipated to become essential in future pemphigus care.